单药本妥昔单抗作为严重肝功能损害的霍奇金淋巴瘤患者的一线治疗：两例报告 - Suppr

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

作者信息

Wang Yupeng, Wang Zi, Wei Chong, Zhao Danqing, Zhang Yan, Wang Wei, Zhang Wei, Zhou Daobin

机构信息

School of Medicine, Tsinghua University, Beijing, China.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100005, China.

出版信息

Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.

DOI:10.1007/s00277-023-05390-4

PMID:37522969

Abstract

摘要

相似文献

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.

Leuk Lymphoma. 2022 Jul;63(7):1768-1769. doi: 10.1080/10428194.2022.2045601. Epub 2022 Mar 6.

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.

Expert Opin Drug Saf. 2016 Jun;15(6):875-82. doi: 10.1080/14740338.2016.1179277. Epub 2016 May 5.

Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.

Ann Hematol. 2022 May;101(5):1149-1152. doi: 10.1007/s00277-021-04709-3. Epub 2021 Nov 10.

Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.

J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373. doi: 10.1093/jpids/piy109.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.

Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.

引用本文的文献

Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.

J Clin Exp Hematop. 2025;65(2):140-145. doi: 10.3960/jslrt.25019.

本文引用的文献

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2.

Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.

J BUON. 2019 Nov-Dec;24(6):2483-2489.

Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment.

Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):e11-4. doi: 10.1016/j.clml.2015.11.015. Epub 2015 Dec 2.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Blood. 2015 Dec 24;126(26):2798-804. doi: 10.1182/blood-2015-06-644336. Epub 2015 Sep 16.

Acute liver failure as the first manifestation of very late relapsing of Hodgkin's disease.

Hematol Rep. 2010 Jan 26;2(1):e5. doi: 10.4081/hr.2010.e5. Epub 2010 Jul 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

作者信息

Wang Yupeng, Wang Zi, Wei Chong, Zhao Danqing, Zhang Yan, Wang Wei, Zhang Wei, Zhou Daobin

机构信息

School of Medicine, Tsinghua University, Beijing, China.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100005, China.

出版信息

Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.

DOI:10.1007/s00277-023-05390-4

PMID:37522969

Abstract

摘要

相似文献

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.

Leuk Lymphoma. 2022 Jul;63(7):1768-1769. doi: 10.1080/10428194.2022.2045601. Epub 2022 Mar 6.

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.

Expert Opin Drug Saf. 2016 Jun;15(6):875-82. doi: 10.1080/14740338.2016.1179277. Epub 2016 May 5.

Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.

Ann Hematol. 2022 May;101(5):1149-1152. doi: 10.1007/s00277-021-04709-3. Epub 2021 Nov 10.

Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.

J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373. doi: 10.1093/jpids/piy109.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.

Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.

引用本文的文献

Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.

J Clin Exp Hematop. 2025;65(2):140-145. doi: 10.3960/jslrt.25019.

本文引用的文献

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2.

Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.

J BUON. 2019 Nov-Dec;24(6):2483-2489.

Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment.

Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):e11-4. doi: 10.1016/j.clml.2015.11.015. Epub 2015 Dec 2.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Blood. 2015 Dec 24;126(26):2798-804. doi: 10.1182/blood-2015-06-644336. Epub 2015 Sep 16.

Acute liver failure as the first manifestation of very late relapsing of Hodgkin's disease.

Hematol Rep. 2010 Jan 26;2(1):e5. doi: 10.4081/hr.2010.e5. Epub 2010 Jul 23.

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献